The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ...

The most common adverse reactions reported with treatment were conjunctival hemorrhage, delayed dark adaptation, foreign body sensation, eye pain, suture related complications, miosis ...

ENCELTO is the First and Only FDA-approved Treatment for MacTel. CUMBERLAND, RI, USA I March 06, 2025 I Neurotech Pharmaceuticals, Inc., a private biotech company focused on d ...

The surgical site should be examined closely and the ENCELTO should be surgically repositioned if indicated. The most common adverse reactions (incidence ≥2%) were conjunctival hemorrhage, delayed ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

The most common adverse reactions reported with Susvimo were conjunctival hemorrhage, conjunctival hyperemia, iritis, eye pain, cataract, conjunctival disorder, and vitreous hemorrhage.

The most common adverse reactions reported with avacincaptad pegol were conjunctival hemorrhage, increased intraocular pressure, blurred vision, and neovascular AMD. The 24- month analysis showed ...

Across the GATHER clinical trial programme, the most common adverse reactions reported with Izervay at 12 months were conjunctival haemorrhage (13%), raised intraocular pressure (9%), and blurred ...

There were no related ocular serious adverse events reported with DSLT. The most common adverse event was mild, self-resolving, punctate sub-conjunctival hemorrhage, which was reported in 20 DSLT ...